Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).Multikine is... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on CEL-SCI CORPORATION
08/18 CEL SCI CORP : Unregistered Sale of Equity Securities, Entry into a Material Def..
08/17 CEL-SCI CORPORATION : Reports Third Quarter Fiscal Year 2017 Financial Results
08/17 CEL SCI : FDA lifts clinical hold on study of Multikine for head and neck cancer
08/15 CEL SCI : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
08/15 CEL SCI CORP : Other Events (form 8-K)
08/14 CEL SCI : NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & N..
08/14 CEL SCI : U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck ..
08/11 CEL SCI CORP : Material Modification to Rights of Security Holders (form 8-K)
08/09 CEL SCI : reports 3Q loss
08/09 CEL SCI : NEW STORY CEL-SCI Extends the Expiration Date of Series DD Warrants Is..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Managers
NameTitle
Geert R. Kersten CEO, CFO, Director & Chief Accounting Officer
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION23
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS26.41%50 145
VERTEX PHARMACEUTICALS101.07%37 346